Advertisement

Drugs

, Volume 61, Issue 7, pp 989–996 | Cite as

Barnidipine

  • Harinder S. MalhotraEmail author
  • Greg L. Plosker
Adis New Drug Profile

Abstract

  • ▴ Barnidipine is an antihypertensive drag belonging to the dihydropyridine (DHP) group of calcium antagonists. It is available in a modified-release formulation which has a gradual onset of action and is effective in a single daily oral dose of 10 to 20mg.

  • ▴ Barnidipine has selective action against cardiovascular calcium antagonist receptors and its antihypertensive action is related to the reduction of peripheral vascular resistance secondary to its vasodilatory action.

  • ▴ The clinical antihypertensive efficacy of barnidipine is similar to that of other DHP calcium antagonists such as nitrendipine and amlodipine, and antihypertensives belonging to other drag classes such as atenolol and enalapril.

  • ▴ Barnidipine has been found to be as efficacious and well tolerated as hydrochlorothiazide in the management of hypertension in elderly patients.

  • ▴ Barnidipine is generally well tolerated. As with other DHP calcium antagonists, vasodilator adverse events such as headache, flushing and peripheral oedema account for most of the adverse events reported with its use and are usually transient. Oedema is less frequent than with amlodipine and nitrendipine. Its use is not associated with reflex tachycardia.

Keywords

Diastolic Blood Pressure Enalapril Atenolol Calcium Antagonist Amlodipine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999 Sep 4; 319: 630–5PubMedCrossRefGoogle Scholar
  2. 2.
    Alderman M, Arakawa K, Beilin L, et al. 1999 World Health Organization — International Society of Hypertension Guidelines for the Management of Hypertension. Blood Press 1999; 8 Suppl. 1: 9–43Google Scholar
  3. 3.
    Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Drugs 1999 Oct; 58: 579–87PubMedCrossRefGoogle Scholar
  4. 4.
    Yamada S, Matsuoka Y, Kato Y, et al. A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats. J Pharmacol Exp Ther 1992 Aug; 262: 589–94PubMedGoogle Scholar
  5. 5.
    Yamada S, Matsuoka Y, Kimura R. Correlation between the plasma concentration of mepirodipine and its occupancy of Ca2+ antagonist receptors in rats. Pharm Res 1993 Sep; 10: 1346–9PubMedCrossRefGoogle Scholar
  6. 6.
    Inagaki O, Asano M, Takenaka T. In vitro and in vivo vasodilatory activity of barnidipine and its enantiomers. Biol Pharm Bull 1999 Feb; 22: 151–6PubMedCrossRefGoogle Scholar
  7. 7.
    van-der-Lee R, Kam KL, Pfaffendorf M, et al. Differential time course of the vasodilator action of various calcium antagonists. Fundam Clin Pharmacol 1998; 12: 607–12PubMedCrossRefGoogle Scholar
  8. 8.
    VasextenTM monograph. Yamanouchi Europe B.VGoogle Scholar
  9. 9.
    Noda H, Fujita T, Ogata E. The role of renal hemodynamics in the antihypertensive action of mepirodipine, a new calcium antagonist. Jpn Circ J 1992 Jan; 56: 21–6PubMedCrossRefGoogle Scholar
  10. 10.
    Argenziano L, Izzo R, Iovino G, et al. Distinct vasodilation, without reflex neurohormonal activation, induced by barnidipine in hypertensive patients. Blood Press Suppl 1998; 1: 9–14PubMedGoogle Scholar
  11. 11.
    Ohya Y, Abe I, Ohta Y, et al. Natriuretic effect of barnidipine, a long-acting dihydropyridine calcium channel blocker, in patients with essential hypertension. Int J Clin Pharmacol Ther 2000 Jun; 38: 304–8PubMedGoogle Scholar
  12. 12.
    Motomura S, Hashimoto K. Reconsideration of vascular selectivity of dihydropyridine calcium antagonists: comparison of cardiovascular profile of mepirodipine, a novel dihydropyridine consisting of a single stereoisomer with (+)-(S)-(S) conformation, with those of nifedipine and nicardipine. Jpn J Pharmacol 1990 Feb; 52: 319–30PubMedCrossRefGoogle Scholar
  13. 13.
    Kimura K, Suzuki N, Mise N, et al. Effects of barnidipine hydrochloride, a calcium channel blocker, on renal microcirculation in rats: A pilot study. Curr Ther Res Clin Exp 1998; 59(12): 826–34CrossRefGoogle Scholar
  14. 14.
    Hashimoto M, Yamauchi T, Ogura T, et al. Treatment with a Ca(2+) channel blocker, barnidipine, reduces platelet-derived growth factor B-chain mRNA in glomeruli of spontaneously hypertensive rats. Am J Nephrol 1999; 19: 615–21PubMedCrossRefGoogle Scholar
  15. 15.
    Kosegawa I, Inaba M, Morita T, et al. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 1998 Oct; 20: 751–61PubMedCrossRefGoogle Scholar
  16. 16.
    Sakai T, Teramura T, Okamiya H, et al. A review on barnidipine: a novel calcium antagonist. Cardiovasc Drug Rev 1997; 15(4): 273–90CrossRefGoogle Scholar
  17. 17.
    Teramura T, Watanabe T, Higuchi S, et al. Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. Xenobiotica 1997 Feb; 27: 203–16PubMedCrossRefGoogle Scholar
  18. 18.
    Teramura T, Tokunaga T, Matsumoto H, et al. Metabolism of barnidipine hydrochloride, a potent calcium antagonist, in rat and dog. Xenobiotica 1996 Feb; 26: 177–87PubMedCrossRefGoogle Scholar
  19. 19.
    Teramura T, Fukunaga Y, Van-Hoogdalem EJ, et al. Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica 1997 Sep; 27: 885–900PubMedCrossRefGoogle Scholar
  20. 20.
    Hart W, Holwerda NJ. Barnidipine, a novel calcium antagonist for once-daily treatment of hypertension: a multicenter, double-blind, placebo-controlled, dose-ranging study. Dutch Barnidipine Multicenter Study Group. Cardiovasc Drugs Ther 1997 Nov; 11: 637–43PubMedCrossRefGoogle Scholar
  21. 21.
    Smilde JG. The long-term efficacy and safety profile of barnidipine. Int J Clin Pract 2000 Nov; 114 Suppl.: 20–6Google Scholar
  22. 22.
    Imai Y, Abe K, Nishiyama A, et al. Evaluation of the antihypertensive effect of barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24h, daytime, and nighttime. Barnidipine Study Group. Am J Hypertens 1997 Dec; 10 (12 Pt 1): 1415–9Google Scholar
  23. 23.
    Smilde JG, Holwerda NJ, Lustermans FAT. Impact of barnidipine on 24-hour ambulatory blood pressure in patients with mild to moderate esential hypertension. J Hypertens 2000 Jun; 18 Suppl. 2: 56Google Scholar
  24. 24.
    Huh WS, Kim YS, Han JS, et al. Antihypertensive efficacy and tolerability of barnidipine hydrochloride in patients with renal parenchymal hypertension. Curr Ther Res Clin Exp 2000 Jul; 61: 395–405CrossRefGoogle Scholar
  25. 25.
    Spieker C. Efficacy and tolerability of once-daily barnidipine in the clinical management of patients with mild to moderate essential hypertension. Blood Press Suppl 1998; 1: 15–21PubMedCrossRefGoogle Scholar
  26. 26.
    Ruilope LM, Coca A. The role of combination therapy in the treatment of hypertension. Blood Press Suppl 1998; 1: 22–6PubMedGoogle Scholar
  27. 27.
    Otterstad JE, Ruilope LM. Treatment of hypertension in the very old. Int J Clin Pract 2000 Nov; 114 Suppl.: 10–9Google Scholar
  28. 28.
    Naber FB, Hage R, Mortelmans J. Barnidipine monotherapy and combination therapy in older patients with essential hypertension: a long-term study. Int J Clin Pract 2000 Nov; 114 Suppl.: 27–35Google Scholar
  29. 29.
    van-der-Velden JW, Beudeker HJ, Nishi M. Diversity and intensity of adverse events in the treatment of hypertension with barnidipine. Blood Press Suppl 1998; 1: 27–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations